Newsfeeds - Spark Newswire

2 minute read

Earnings

Looking Into LivaNova’s Return On Capital Employed

Today, 5:36 PM

Pulled from Benzinga Pro data, LivaNova (NASDAQ:LIVN) posted Q1 earnings of $2.99 million, an increase from Q4 of 134.94%. Sales dropped to $240.20 million, a 11.07% decrease between quarters.

LIVN

57 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 5:36 PM

On Friday, 1043 companies hit new 52-week lows.

AAOI

2 minute read

Analyst Ratings

Analyst Ratings for LivaNova

By Benzinga Insights

Today, 5:36 PM

Within the last quarter, LivaNova (NASDAQ:LIVN) has observed the following analyst ratings:

LIVN

1 minute read

LivaNova (NASDAQ:LIVN) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings LivaNova reported in-line EPS of $0.48 versus an estimate of $0.48.

LIVN

1 minute read

LivaNova Q1 Adj. EPS $0.48, Inline, Sales $240.20M Beat $231.57M Estimate

By Bill Haddad

Today, 5:36 PM

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $0.48 per share which met the analyst consensus estimate. This is a 37.14 percent increase over earnings of $0.35 per share from the same period last year. The

LIVN

27 minute read

Earnings Scheduled For May 4, 2022

By Benzinga Insights

Today, 5:36 PM

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

16 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For April 6, 2022

By Benzinga Insights

Today, 5:36 PM

Upgrades

ABMD

3 minute read

LivaNova Reports Patient Implanted In OSPREY Study For Patients Coping With Obstructive Sleep Apnea

By Benzinga Newsdesk

Today, 5:36 PM

Study to evaluate effectiveness of hypoglossal nerve stimulation LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the first patient

LIVN